Fish Oil Supplementation in Late-life Depression

Taipei City Psychiatric Center, Taiwan

Status: Completed

Conditions: Late-Life Depression

Treatments: Dietary Supplement: N-3 polyunsaturated fatty acids

Study type: Interventional

Funder types: Other

Identifiers

NCT01235533

95004-62-161

Details and patient eligibility

About

To investigate whether fish oil supplementation, compared to placebo (olive oil), could have better effects on depression course and cognitive function in older people with major depression.

Full description

Patients with late-life depression were reported cognitive impairment, especially in information-processing speed, working memory, attention and episodic memory, even after depressive symptoms subside and some of them further progress to dementia in two to four years. Several epidemiological studies, fatty acid comparison studies, animal studies, and clinical trials found that omega-3 polyunsaturated fatty acids (PUFAs) were significantly associated with the major depression, cognitive decline in general population and Alzheimer's disease. Until now, there is no study investigating the effects of n-3 PUFAs on depressive symptoms and cognition in patients with late-life depression. Thus, the aims of this study were to investigate whether fish oil supplementation, compared to placebo (olive oil), could have better effects on depression course and cognitive function in older people with major depression.

Enrollment: 89 patients

Sex: All

Ages: 60+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• An age range of 60 years old or over;
• A previous diagnosis of major depressive disorder according to the Chinese version of Structured Clinical Interview for DSM IV-TR Axis-I Disorder;
• Depressive symptoms were stable for at least three consecutive weeks and the 17-item Hamilton Depression Rating Scale score less or equal to 10.
• Capacity to provide informed consent.

Exclusion criteria

• People with severe or acute medical illness ( such as metastatic cancer, brain tumor, decompensated cardiac, hepatic, or renal failure, or myocardial infarction or stroke) within the 3 months preceding the study.
• Those who had neurological disorders involving central nervous system, such as delirium, Parkinson's disease, aphasia or multiple sclerosis)
• Prominent cognitive impairment, defined as the Chinese version of Mini-Mental State examination score less than 17.
• People with alcoholism, defined by a score of 8 or higher in male and of 6 or higher in female on the Chinese version of the Alcohol Use Disorders Identification Test (AUDIT) questionnaire.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

89 participants in 2 patient groups, including a placebo group

N-3 fatty acids

Experimental group

Description:

Participants in this arm were received three capsules of n-3 fatty acids. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g。

Treatment:

Dietary Supplement: N-3 polyunsaturated fatty acids

Placebo

Placebo Comparator group

Description:

Participants in this arm were received three identical capsules per day. All capsules included olive oil.

Treatment:

Dietary Supplement: N-3 polyunsaturated fatty acids